3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
10
Hot Flashes
2
Anxiety Disorders
2
Vomiting
1
Testicular Germ Cell Tumor
1
Smoking Cessation
1
Sarcoma
1
Pathophobia
1
Pain
1
Ovarian Neoplasms
1
Nausea
1
Musculoskeletal Pain
1
Melanoma
1
Medication Adherence
1
Inflammatory Breast Neoplasms
1
Gastrointestinal Neoplasms
1
Emotional Regulation
1
Depression
1
Breast Carcinoma In Situ
1
Breast Cancer Surgery
1
Affective Symptoms
1
Interventions
Surveys and Questionnaires
7
Nivolumab
5
atezolizumab
3
Radiosurgery
3
Blood Specimen Collection
3
pertuzumab
2
pembrolizumab
2
pazopanib
2
cemiplimab
2
amminedichloro(2-methylpyridine)platinum(II)
2
alectinib
2
Magnetic Resonance Spectroscopy
2
Interviews as Topic
2
Drug Therapy
2
Capecitabine
2
tepotinib
1
talazoparib
1
selpercatinib
1
pralsetinib
1
ponatinib
1
pemigatinib
1
palbociclib
1
motexafin gadolinium
1
montanide ISA 51
1
mannide monooleate
1
itacitinib
1
ipatasertib
1
fludarabine
1
entrectinib
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
Hypnosis
×
Breast
×
Clear all
NCT04899492
2024-11-07
RESPIRE
Institut Cancerologie de l'Ouest
Phase NA
Terminated
22 enrolled